Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

TRACON Pharmaceuticals Q3 EPS $(0.38), Same YoY

TRACON Pharmaceuticals (NASDAQ:TCON) reported quarterly losses of $(0.38) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

November 3, 2021

1 minute read

TRACON Pharmaceuticals (NASDAQ:TCON) reported quarterly losses of $(0.38) per share. This is unchanged from the same period last year.

Legal
News

UPDATE: Legal Data Transparency Advocate, PlainSite, Publishes ‘FTC DoorDash FOIA Response Documents’

By Benzinga Newsdesk

September 23, 10:29 AM

https://www.plainsite.org/documents/2t8bt7/ftc-doordash-foia-response-documents/

DASH

QuantumScape Inks Strategic Multi-Year Agreement With Fluence

By Shivani Kumaresan

January 13, 3:10 PM

QuantumScape Corp (NYSE:QS) has signed a multi-year agreement with Fluence Energy Inc (NASDAQ:FLNC) to introduce solid-state lithium-metal battery technology to stationary energy storage…

FLNC

RBC Capital Maintains Sector Perform on Envestnet, Raises Price Target to $89

By Benzinga Newsdesk

November 9, 8:59 AM

RBC Capital analyst Daniel Perlin maintains Envestnet (NYSE:ENV) with a Sector Perform and raises the price target from $84 to $89.

ENV

Aegis Capital Initiates Coverage On Trevi Therapeutics with Buy Rating, Announces Price Target of $10

By Benzinga Newsdesk

March 29, 9:08 AM

Aegis Capital analyst Nathan Weinstein initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $10.

TRVI

TRACON Pharmaceuticals Q3 EPS $(0.38), Same YoY

Related Posts

UPDATE: Legal Data Transparency Advocate, PlainSite, Publishes ‘FTC DoorDash FOIA Response Documents’

QuantumScape Inks Strategic Multi-Year Agreement With Fluence

RBC Capital Maintains Sector Perform on Envestnet, Raises Price Target to $89

Aegis Capital Initiates Coverage On Trevi Therapeutics with Buy Rating, Announces Price Target of $10